Zhu L, et al. - Researchers assessed the role of CDK5 (cyclin-dependent kinase 5) in ccRCC (clear cell Renal Cell Carcinoma) prognosis, by analyzing data from both of The Cancer Genome Atlas and Gene Expression of Normal and Tumor Tissue. They performed immunohistochemistry (IHC) analysis using tissue microarray that was constructed by using 150 ccRCC samples. From Oncomine database, a validation of overall survival cohort was obtained. Participants were ccRCC patients (n=150) who had nephrectomy, including 107 male and 43 female (mean age 57.0 years). The role of CDK5 as a promising biomarker in ccRCC patients was evident for the first time ever in this study. For overall survival, the identified independent prognostic factor was co-expression of CDK5 and p21. Based on the findings, they concluded that IHC analysis of CDK5 and p21 on cancer tissues post-operation could aid to assess and predict the result of ccRCC patients.